Archford Capital Strategies LLC Has $3.21 Million Stake in Cencora, Inc. (NYSE:COR)

Archford Capital Strategies LLC decreased its holdings in Cencora, Inc. (NYSE:COR) by 28.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,554 shares of the company’s stock after selling 4,495 shares during the quarter. Archford Capital Strategies LLC’s holdings in Cencora were worth $3,213,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Net Worth Advisory Group increased its holdings in Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock valued at $736,000 after buying an additional 36 shares during the period. Whittier Trust Co. increased its position in Cencora by 0.6% during the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock worth $1,765,000 after purchasing an additional 44 shares in the last quarter. Cullen Frost Bankers Inc. increased its position in Cencora by 1.1% during the 4th quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock worth $1,003,000 after purchasing an additional 47 shares in the last quarter. Permanent Capital Management LP increased its position in Cencora by 4.0% in the 1st quarter. Permanent Capital Management LP now owns 1,238 shares of the company’s stock valued at $344,000 after acquiring an additional 48 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in Cencora by 4.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock valued at $307,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $294.16 on Wednesday. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The firm has a market capitalization of $57.02 billion, a PE ratio of 34.13, a P/E/G ratio of 1.45 and a beta of 0.58. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a 50-day moving average price of $289.36 and a two-hundred day moving average price of $263.98.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts’ consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $3.80 earnings per share. Equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a $0.55 dividend. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. Cencora’s dividend payout ratio (DPR) is currently 25.52%.

Insider Activity

In other news, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the transaction, the chairman now directly owns 315,913 shares in the company, valued at approximately $89,027,442.53. This trade represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares of the company’s stock, valued at $13,766,900.06. This trade represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a research report on Tuesday, April 29th. Bank of America raised their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Citigroup raised their price objective on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Finally, Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $306.91.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.